Metraipolis › archive › dc_48a94fc25484

Recommendations for the use of clinical outcome assessments in rare disease drug development — Europe PMC PMID:42495108

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42495108
DOI
10.1016/j.eclinm.2026.104073
License (as archived)
solo-consultazione
Archived
2026-10-18T03:24:28.806Z
SHA-256 of the archived text
932edb61214ffe5c0ddf485b8dc21e3d553a5a0d6b4b6fd858594b2b69a55312
Stable URL of this page
https://metraipolis.com/documento/dc_48a94fc25484

How to cite

Recommendations for the use of clinical outcome assessments in rare disease drug development — Europe PMC PMID:42495108 — Europe PMC (en), https://europepmc.org/article/MED/42495108 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_48a94fc25484 (Metraipolis archive dc_48a94fc25484, sha256 932edb61214ffe5c0ddf485b8dc21e3d553a5a0d6b4b6fd858594b2b69a55312)
BibTeX
@misc{dc48a94fc25484,
  title = {Recommendations for the use of clinical outcome assessments in rare disease drug development — Europe PMC PMID:42495108},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42495108},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_48a94fc25484; sha256 932edb61214ffe5c0ddf485b8dc21e3d553a5a0d6b4b6fd858594b2b69a55312},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42495108. Agents can read the archived copy with the MCP tool read_document.